Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Authors:
- Christine N. DuncanCDChristine N. Duncan
- Jacob R. BledsoeJBJacob R. Bledsoe
- Bartosz GrzywaczBGBartosz Grzywacz
- Amy BeckmanABAmy Beckman
- Melissa BonnerMBMelissa Bonner
- Florian S. EichlerFEFlorian S. Eichler
- Jörn-Sven KühlJKJörn-Sven Kühl
- Marian H. HarrisMHMarian H. Harris
- Sarah SlausonSSSarah Slauson
- Richard A. ColvinRCRichard A. Colvin
- Vinod K. PrasadVPVinod K. Prasad
- Gerald F. DowneyGDGerald F. Downey
Top Cited Papers
- 10 October 2024
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (14) , 1287-1301
Abstract
Gene therapy with elivaldogene autotemcel (eli-cel) consisting of autologous CD34+ cells transduced with lentiviral vector containing ABCD1 complementary DNA (Lenti-D) has shown efficacy in clinical studies for the treatment of cerebral adrenoleukodystrophy. However, the risk of oncogenesis with eli-cel is unclear. We performed integration-site analysis, genetic studies, flow cytometry, and morphologic studies in peripheral-blood and bone marrow samples from patients who received eli-cel therapy in two completed phase 2-3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304) involving the patients in both ALD-102 and ALD-104. Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel (1 of 32 patients in the ALD-102 study and 6 of 35 patients in the ALD-104 study): myelodysplastic syndrome (MDS) with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 patients at 28, 42, and 92 months; MDS in 1 patient at 36 months; and acute myeloid leukemia (AML) in 1 patient at 57 months. In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including at either MECOM-EVI1 (MDS and EVI1 complex protein EVI1 [ecotropic virus integration site 1], in 5 patients) or PRDM16 (positive regulatory domain zinc finger protein 16, in 1 patient). Several patients had cytopenias, and most had vector insertions in multiple genes within the same clone; 6 of the 7 patients also had somatic mutations (KRAS, NRAS, WT1, CDKN2A or CDKN2B, or RUNX1), and 1 of the 7 patients had monosomy 7. Of the 5 patients with MDS with excess blasts or MDS with unilineage dysplasia who underwent allogeneic hematopoietic stem-cell transplantation (HSCT), 4 patients remain free of MDS without recurrence of symptoms of cerebral adrenoleukodystrophy, and 1 patient died from presumed graft-versus-host disease 20 months after HSCT (49 months after receiving eli-cel). The patient with AML is alive and had full donor chimerism after HSCT; the patient with the most recent case of MDS is alive and awaiting HSCT. Hematologic cancer developed in a subgroup of patients who were treated with eli-cel; the cases are associated with clonal vector insertions within oncogenes and clonal evolution with acquisition of somatic genetic defects. (Funded by Bluebird Bio; ALD-102, ALD-104, and LTF-304 ClinicalTrials.gov numbers, NCT01896102, NCT03852498, and NCT02698579, respectively.).Keywords
Funding Information
- bluebird bio
This publication has 36 references indexed in Scilit:
- Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessThe Lancet, 2022
- Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic DisordersTransplantation and Cellular Therapy, 2020
- Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus MacaqueMolecular Therapy, 2019
- Clonal analysis of lineage fate in native haematopoiesisNature, 2018
- Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysisBone Marrow Transplantation, 2015
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison studyThe Lancet Neurology, 2007
- X-linked adrenoleukodystrophyNature Clinical Practice Neurology, 2007
- Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integrationNature Biotechnology, 2006
- Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1Nature Medicine, 2006